TScan Therapeutics Announces 75% Workforce Reduction and Strategic Reorganization to Prioritize Solid Tumor Program

TScan Therapeutics, Inc. initiated a prioritization strategy, leading to a workforce reduction of approximately 75% of its employees. The company will focus on the preclinical development of its in vivo solid tumor program and pause further enrollment in its Phase 3 ALLOHA-2™ study of TSC-101. The strategic reorganization is expected to be substantially complete by the end of the fourth quarter of 2026, incurring approximately $4.1 million in employee-related costs.